Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis
Prostate cancer (CaP) is a heterogeneous disease with high variability in regards to clinical outcome and therapeutic response. While some men will develop an indolent CaP not affecting life expectancy, others might die of CaP. Thus, the process of screening and diagnosing, as well as the therapeutic options and monitoring can be difficult for the urologist —to distinguish between lethal and indolent CaP still remains a challenge.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: In ês Anselmo da Costa, Jörg Hennenlotter, Viktoria Stühler, Ursula Kühs, Marcus Scharpf, Tilman Todenhöfer, Arnulf Stenzl, Jens Bedke Tags: Original article Source Type: research